ChemPartner PharmaTechLtd 관리

관리 기준 확인 0/4

ChemPartner PharmaTechLtd CEO는 Swee Lian Woo, Jan2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 CN¥ 153.07M 가치에 해당하는 회사 주식의 4.56% 직접 소유합니다. 153.07M. 경영진과 이사회의 평균 재임 기간은 각각 1.6 년과 2.5 년입니다.

주요 정보

Swee Lian Woo

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	4.6%
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	2.5yrs

최근 관리 업데이트

Recent updates

ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Price Is Right But Growth Is Lacking After Shares Rocket 51%

Sep 30

Improved Revenues Required Before ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) Stock's 29% Jump Looks Justified

Aug 04

Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Mar 08

CEO

Swee Lian Woo (63 yo)

less than a year

테뉴어

Mr. Swee Lian Woo is President of Perfect (China) Co., Ltd. He is Director of RRTC, Inc. He serves as General Manager and Chairman of Chempartner Pharmatech Co., Ltd. since January 10, 2024.He was Chairma...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jian Xu	Board Secretary	3yrs	CN¥1.44m	데이터 없음
Zhenjia Chen	Vice President	1.6yrs	CN¥1.78m	데이터 없음
Swee Lian Woo	GM & Chairman	less than a year	데이터 없음	4.56% CN¥ 153.1m

1.6yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 관리: 300149 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Swee Lian Woo	GM & Chairman	less than a year	데이터 없음	4.56% CN¥ 153.1m
Xin Hui	Director	6.3yrs	CN¥360.00k	데이터 없음
Xuemei Zhang	Independent Director	no data	데이터 없음	데이터 없음
Rong Yu	Director	less than a year	데이터 없음	데이터 없음
Dachao Zhang	Chairman of the Supervisory Board	3.3yrs	데이터 없음	데이터 없음
Zhicheng Guo	Independent Director	4.2yrs	CN¥80.00k	데이터 없음
Shi Xin Fan	Director	3yrs	CN¥1.03m	데이터 없음
Xianzhong Wang	Independent Director	3.3yrs	CN¥80.00k	0.00030% CN¥ 10.1k
Jiahui Qi	Supervisor	6.3yrs	데이터 없음	0.0084% CN¥ 282.9k
Ling Yang	Independent Director	1.9yrs	CN¥80.00k	데이터 없음
Man Ngar Wong	Employee Supervisor	1.7yrs	데이터 없음	데이터 없음
Wanglong Chen	Non-Independent Director	no data	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 이사회: 300149 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

ChemPartner PharmaTechLtd 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

ChemPartner PharmaTech Co.,Ltd. Approves the Election of Directors

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

Less than half of directors are independent

Recent updates

ChemPartner PharmaTech Co.,Ltd. Approves the Election of Directors

ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Price Is Right But Growth Is Lacking After Shares Rocket 51%

ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)

Improved Revenues Required Before ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) Stock's 29% Jump Looks Justified

ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)

New minor risk - Share price stability

Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)

Investor sentiment deteriorates as stock falls 18%

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)

Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Tate & Lyle plc (LSE:TATE) completed the acquisition of Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in funding

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2021 Results on Apr 30, 2022

Less than half of directors are independent

Tate & Lyle plc (LSE:TATE) signed an agreement to acquire Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for $237 million.

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.085 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)

Investor sentiment improved over the past week

Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 June 2021

Chempartner Pharmatech Co., Ltd. Approves Cash Dividend for the Year 2020

Investor sentiment improved over the past week

Chempartner Pharmatech Co., Ltd. Announces the Profit Distribution Proposal for 2020

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)

New 90-day low: CN¥12.64

New 90-day low: CN¥12.66

Investor sentiment deteriorated over the past week

New 90-day low: CN¥14.46

New 90-day low: CN¥18.29

Third quarter earnings released

New 90-day high - CN¥23.98

First half earnings released

Quantum Hi-Tech (China) Biological Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥22.71

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령